Syngene International Ltd
Syngene International Q2 Results 2026 (FY27) investor presentation: Revenue & Order Book
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Top 10 Healthcare Services companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Syngene International Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2 FY27 Revenue from Operations: Rs.
From Syngene International Ltd's Q2 FY27 earnings-call transcript · updated 27 Oct 2026.
Revenue & Sales Performance
- Q2 FY27 Revenue from Operations: Rs. 833 Cr, down 9% YoY (Q2 FY26: Rs. 911 Cr)
- Reported revenue for Q2 FY27: Rs. 861 Cr, down 7% YoY (Q2 FY26: Rs. 926 Cr)
- H1 FY27 Revenue from Operations: Rs. 1,569 Cr, down 12% YoY
- Q2 FY27 Operating EBITDA Margin: 18%, lower than 22% in Q2 FY26
2 more points from Syngene International Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Syngene International Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Acquired 17 acres land in Hyderabad to support long-term growth in research business.
- Acquired state-of-the-art first biologics site in Baltimore, USA, increasing single-use bioreactor capacity to 50,000L.
- Expansion in Mangalore for commercial API manufacturing.
- Capacity and capability addition in biologics manufacturing.
- Laboratory capacity expansion in Bangalore and Hyderabad.
- Bayview Biologics Facility: Signed first manufacturing agreement; process development to begin in India this year, drug-substance manufacturing at Bayview to start next year.
2 more points from Syngene International Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Syngene International Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Syngene International Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹833 Cr, net profit ₹32 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Syngene Intl.'s management said in earlier quarters
- Q1 FY26 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY27 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Healthcare Services this season
- Narayana Hrudayalaya Ltd (Q2 FY27)
Consolidated operating revenue for Q2 FY27: ₹28,440 Mn, up 73.0% YoY (Page 15, 16). Key investor presentation takeaways from Narayana Hrudayalaya Ltd's Q2 FY27
- Artemis Medicare Services Ltd (Q2 FY27)
Q2 FY27 consolidated revenue from operations: INR 31,104 Lacs, up 13.2% YoY (Page 39, 40, 20). Key investor presentation takeaways from Artemis Medicare Service
- Max Healthcare Institute Ltd (Q2 FY27)
Q2 FY27 Gross Revenue: ₹3,219 Cr, up 20% YoY (Page 4, 17) . Key investor presentation takeaways from Max Healthcare Institute Ltd's Q2 FY27 investor presentatio
- Indegene Ltd (Q2 FY27)
Revenue from operations for Q2 FY27: INR 11,223 million, up 39.5% YoY (Page 23, 15, 4) . Key investor presentation takeaways from Indegene Ltd's Q2 FY27 investo
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- Aster DM Quality Care LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Syngene International Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Syngene International Ltd Q2 FY27 results?
Q2 FY27 Revenue from Operations: Rs.
What is Syngene International Ltd share price analysis?
Syngene International Ltd currently shows a neutral. The stock trades at a P/E of 49.9 with a market cap of ₹14,782 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Syngene International Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.